Beta Amyloid News and Research

RSS

Clinical study shows positive effects of CAD106 vaccine against AD

A study led by Karolinska Institutet in Sweden reports for the first time the positive effects of an active vaccine against Alzheimer's disease. The new vaccine, CAD106, can prove a breakthrough in the search for a cure for this seriously debilitating dementia disease. The study is published in the distinguished scientific journal Lancet Neurology.

7 Jun 2012

Immune system involved in removing Alzheimer's-causing substance in the brain

Recent work in mice suggested that the immune system is involved in removing beta-amyloid, the main Alzheimer's-causing substance in the brain. Researchers have now shown for the first time that this may apply in humans.

25 May 2012

Omega-3 fatty acids may provide more benefits for elderly people with Alzheimer's

According to a recent study published online in Neurology, Omega-3 fatty acids, like those found in Omega XL fish oil extract containing DHA and EPA from the New Zealand green-lipped mussel, may provide more benefits for elderly people suffering from Alzheimer's.

24 May 2012

Scientists identify key mechanism in development of Alzheimer's

New research by scientists at the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine (UMDNJ-SOM) demonstrates how dying or damaged brain cells release debris into the bloodstream and give rise to specific autoantibodies that appear to be reliable biomarkers for early diagnosis of Alzheimer's and other neurodegenerative diseases.

23 May 2012

Intellect Neurosciences announces two new programs in Alzheimer's disease development pipeline

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.

7 May 2012

Foods rich in omega-3 fatty acids linked with lower blood beta-amyloid levels

A new study suggests that eating foods that contain omega-3 fatty acids, such as fish, chicken, salad dressing and nuts, may be associated with lower blood levels of a protein related to Alzheimer's disease and memory problems.

3 May 2012

New drug to detect beta-amyloid plaques may help diagnose AD earlier

Use of a new drug to detect the beta-amyloid plaques in the brain that are hallmark signs of Alzheimer's disease may help doctors diagnose the disease earlier, according to research that will be presented as part of the Emerging Science program (formerly known as Late-Breaking Science) at the American Academy of Neurology's 64th Annual Meeting in New Orleans April 21 to April 28, 2012.

16 Apr 2012

Florbetaben PET scan reliably identifies beta-Amyloid in the brain

Piramal Imaging SA, a newly formed subsidiary of Piramal Healthcare Limited, announced positive first results from a Phase III study that showed that PET imaging with florbetaben reliably detects beta-Amyloid in the brain during life with great accuracy and thus shows value as a potential tool to aid in the diagnosis and assessment of Alzheimer's disease.

16 Apr 2012

Preliminary results from GE Healthcare’s flutemetamol Phase 3 studies on AD

GE Healthcare today announced the preliminary results of two Phase 3 studies of its investigational PET amyloid imaging agent, [18F]flutemetamol, where both studies met their primary endpoints. One study, in terminally ill patients who agreed to undergo brain autopsy, showed strong concordance between flutemetamol PET images and Alzheimer's disease-associated beta amyloid brain pathology.

12 Apr 2012

Siemens announces integrated imaging solution for detection of amyloid plaques

Siemens Healthcare is the first company worldwide to announce a complete integrated diagnostic imaging solution proposed for the detection of amyloid plaques — one of the necessary pathological features of Alzheimer's disease— in the living brain.

From Siemens Healthineers 11 Apr 2012

Reducing iron levels in blood plasma may protect brain from changes related to AD

Alzheimer's disease (AD) is now the sixth leading cause of death among Americans, affecting nearly 1 in 8 people over the age of 65. There is currently no treatment that alters the course of this disease. However, an increasing amount of evidence suggests that changes in the way the body handles iron and other metals like copper and zinc may start years before the onset of AD symptoms. A new study shows that reducing iron levels in blood plasma may protect the brain from changes related to AD.

11 Apr 2012

Elevated pulse pressure may increase risk of CVD in older adults with AD

Researchers at the University of California, San Diego and Veterans Affairs San Diego Healthcare System have shown that elevated pulse pressure may increase the risk of cerebrovascular disease (CVD) in older adults with Alzheimer's disease.

7 Apr 2012

Lilly, Avid receive FDA approval for Amyvid to treat Alzheimer's

Eli Lilly and Company and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline.

7 Apr 2012

New SORL1 gene causes early-onset Alzheimer's

A new gene that causes early-onset of Alzheimer's disease has been discovered by the research team of Dominique Campion at the Insert unit 1079 "Genetics of cancer and neuropsychiatric diseases" in Rouen.

5 Apr 2012

Study reveals mechanism by which AD may cause memory loss

Alzheimer's disease (AD) steals memory and ruins lives. Despite near-daily reports of promising new therapies, AD remains unchecked. Now a new study reveals the mechanism by which AD may cause memory loss, suggesting new therapies.

26 Mar 2012

New method for measurement of aggregated beta-amyloid in AD

An international team of researchers have developed a new method for measurement of aggregated beta-amyloid - a protein complex believed to cause major nerve cell damage and dysfunction in Alzheimer's disease. The new method might facilitate diagnosis and detection as well as development of drugs directed against aggregated beta-amyloid.

26 Mar 2012

ApoE4 gene could cause early loss of synapses in Alzheimer's disease

Today, researchers at the Blanchette Rockefeller Neurosciences Institute (BRNI) at West Virginia University in Morgantown, West Virginia reported a significant advance in understanding how different forms of the ApoE gene raise the risk for Alzheimer's disease.

17 Mar 2012

Intellect Neurosciences receives U.S. patent allowance for ANTISENILIN to treat AD

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases announced today that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent claims covering the company's ANTISENILIN monoclonal antibody platform technology for the treatment and prevention of Alzheimer's disease.

7 Mar 2012

HDAC2 enzyme could be a potential target for new Alzheimer's drugs

MIT neuroscientists have shown that an enzyme overproduced in the brains of Alzheimer's patients creates a blockade that shuts off genes necessary to form new memories. Furthermore, by inhibiting that enzyme in mice, the researchers were able to reverse Alzheimer's symptoms.

1 Mar 2012

Disrupted sleep may raise risk of Alzheimer’s disease

According to a new study, which will be presented at the American Academy of Neurology's 64th Annual Meeting in New Orleans, April 21st to April 28th, the amount of sleep people get may later affect their memory's function and the risk of Alzheimer's.

15 Feb 2012